Overview

When
Monday, November 9, 2015 -
 Tuesday, November 10, 2015
Where
Renaissance Arboretum Hotel
9721 Arboretum Boulevard
Austin, Texas 78759
USA

Event Coverage

Photo Gallery

Please see below for a selection of images from our 2015 Innovations conference. Click an image below to see a larger version.

Program Book

For an offline version of conference speakers, sessions and abstract information, please review our conference program book.


 


Schedule

See below for the current listing of the sessions at our 2015 Innovations conference. Please note that this schedule is subject to change and will updated as soon as any changes are made.

Session Legend

    Plenary     Research     Prevention     Product Development     Joint     Posters     General

Monday, November 9

8:30 AM
Welcome 
Speakers

Wayne Roberts 
Cancer Prevention and Research Institute of Texas

Mr. Roberts was named CEO of the Cancer Prevention and Research Institute of Texas (CPRIT) in November 2013 after serving since December 2012 as the interim executive director. Prior to four years with The University of Texas Health Science Center at Houston as associate vice president for public policy, his career was weighted towards public finance and budget, especially with respect to higher education.  He held numerous senior positions under Governor Rick Perry in which, among other things, he authored the white paper and draft legislation creating the Texas Emerging Technology Fund to catalyze economic development, including transferring research conducted at universities to the Texas marketplace. He was Lieutenant Governor Bob Bullock’s special assistant for budget and human services following 18 years with the Legislative Budget Board. Mr. Roberts received a bachelor's degree with honors and special honors in government from The University of Texas at Austin and a master's from the Lyndon B. Johnson School of Public Affairs at UT. 

Pete Geren 
CPRIT Oversight Committee

Mr. Geren is the president of the Sid W. Richardson Foundation, which provides grants to educational, health, human service and cultural nonprofit organizations in Texas. From 2001 to 2009, he served in the U.S. Department of Defense as special assistant to the secretary of defense, acting secretary of the Air Force, under secretary of the Army and secretary of the Army. He also served four terms in the U.S. House of Representatives and was formerly assistant to U.S. Sen. Lloyd Bentsen. Geren received his bachelor's from The University of Texas in 1974 and a law degree from The University of Texas Law School in 1978.

Presentations


8:45 AM
The Promise and Perils of Immunotherapy 

Harnessing the immune system to combat cancer has been an elusive goal in the history of cancer therapy. Recent advances in our understanding of how the immune system is regulated provide new optimism that immunotherapy can be an effective addition to other forms of cancer treatment. Three such approaches to immunotherapy will be presented by CPRIT grantees. A brief panel discussion on the promise and pitfalls of immunotherapy will follow the presentations.

Moderators

Margaret Kripke, PhD 
CPRIT

Dr. Kripke has served as CPRIT's chief scientific officer since January 2013. Previously, she was the executive vice president and chief academic officer at The University of Texas MD Anderson Cancer Center. During her tenure there, Dr. Kripke founded the Department of Immunology and was also a professor of immunology. She served for almost a decade on the three-person President's Cancer Panel, an honor reserved for the most distinguished oncology scientists in the nation. She holds a doctorate in immunology from the University of California at Berkeley and is a world-renowned expert in the immunology of skin cancers. Due to her esteemed position within the scientific community, particularly as a champion of diversity in the workplace, the Margaret L. Kripke Legend Award was established by MD Anderson in 2008 to honor individuals who have enhanced the careers of women in cancer medicine and cancer science.

Speakers

Jim Allison, PhD 
The University of Texas MD Anderson Cancer Center

Dr. Allison serves as the chair of The University of Texas MD Anderson Cancer Center Immunology Department and is the executive director of the Moon Shots Program Immunotherapy Platform. Dr. Allison's pioneering research has led to treatment that unleashes the body's immune system against cancer, and to the the approval of Yervoy, which became the first FDA approved checkpoint inhibitor when it was authorized for the treatment of advanced melanoma in 2011. This year, Dr. Allison was named winner of the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific awards. He also received the Science of Oncology Award by ASCO and the Pezcoller Foundation–AACR International Award for Cancer Research. Dr. Allison received the Giants of Cancer Care award for scientific advances in 2014. A CPRIT grant helped bring him back to his native Texas in 2012. 

Malcolm Brenner, MD, PhD 
Baylor College of Medicine

Dr. Brenner is the founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine (BCM), Texas Children’s Hospital and The Methodist Hospital. Currently, he serves as a professor in the Departments of Pediatrics and of Medicine at BCM. Dr. Brenner’s clinical research interests span many aspects of stem cell transplantation, using genetic manipulation of cultured cells to obtain therapeutic effects. Efforts in his laboratory to analyze the cell of origin when relapse occurs in patients with acute myelogenous leukemia led Brenner’s team to be the first to label autologous bone marrow cells genetically after purging, prior to being reintroduced to the patient. He is studying the effects of gene transfer into autologous neuroblastoma cells and the use of gene-modified EBV-specific cytotoxic T lymphocytes for prevention and treatment of lymphoproliferative disorders, Hodgkin’s disease, lung cancer and neuroblastoma. His group recently pioneered the first clinical use of a new safety switch for cellular therapy. Dr. Brenner is editor-in-chief of Molecular Therapy and a former president of the American Society for Gene and Cell Therapy (ASGCT) and the International Society for Cell Therapy. He has won many awards for his work, including the ASGCT Outstanding Achievement award and the American Society of Hematology Mentor award. Dr. Brenner received his PhD and medical degree from Cambridge University, England.

Cassian Yee, MD 
The University of Texas MD Anderson Cancer Center

Dr. Yee is a professor in the Department of Melanoma Medical Oncology and Department of Immunology at The University of Texas MD Anderson Cancer Center. He serves as the director of the Solid Tumor Cell Therapy program there. Dr. Yee is a recipient of the Cancer Research Institute Investigator Award and the Damon Runyon Walter Winchell Clinical Investigator Award. He is also a Burroughs Wellcome Scientist in Translational Research, an elected member of the American Society for Clinical Investigation, and co-leader of the Stand Up to Cancer Immunology Dream Team. His research was among the first to show that adoptive T-cell therapy holds great promise for treating melanoma. Additionally, he demonstrated for the first time that human T cells can become long-lasting memory cells after infusion and, when combined with a checkpoint inhibitor, halt tumor growth in patients with metastatic melanoma.  CPRIT funding helped bring him to Texas from the Fred Hutchinson Cancer Research Center at the University of Washington. 

Presentations


10:30 AM
Coffee Break

10:45 AM
Modern Epidemiology: Dark Wood, Glimmer of Hope 

This session explores the importance of the "big picture" in patient care and health promotion at the population level. The case will be made for consensus on priority behavioral risk reduction strategies that have the greatest impact on population health. The value of a holistic approach to clinical care will be discussed, as will the potential of a short list of lifestyle factors to eliminate up to 80 percent of all chronic disease. 

Speakers

David Katz, MD, MPH 
Yale University

Dr. Katz is the founding director of Yale University’s Prevention Research Center, president of the American College of Lifestyle Medicine, editor-in-chief of the journal Childhood Obesity, chief science officer for NuVal LLC, and director of the Integrative Medicine Center at Griffin Hospital. A clinician, researcher, author, inventor, and journalist, Dr. Katz has authored nearly 200 scientific papers and chapters, 15 books, and hundreds of online columns and blogs, with a resulting social media following of more than 400,000.  A two-time diplomat of the American Board of Internal Medicine and a board-certified specialist in preventive medicine and public health, he is recognized globally for expertise in nutrition, weight management, and the prevention of chronic disease.  Dr. Katz earned his undergraduate degree from Dartmouth College, his medical degree from the Albert Einstein College of Medicine and his master's in public health from the Yale University School of Public Health. The recipient of numerous awards and recognitions, Dr. Katz has been a widely supported nominee for the position of U.S. surgeon general, and has been recognized by Greatist.com as one of the 100 most influential people in health and fitness in the world. 

Presentations


11:30 AM
Lunch Provided - No Program

12:30 PM
Environmental Chemicals and Breast Cancer: What Do We Know? 
Dr. Brody reviews the chemical pathways to breast cancer, evaluates the concordance between animal and human evidence, and considers what types of evidence should guide risk reduction. She'll discuss new rapid-screening technologies that can be adapted from drug discovery for use in testing consumer product chemicals for safety. Participants will learn about compelling new research opportunities and discover how to communicate with patients and public health leaders about what is known and yet to be discovered about environmental links to breast cancer.
Speakers

Julia Brody, PhD 
Silent Spring Institute

Dr. Brody is the executive director of Silent Spring Institute and a leader in research on breast cancer and the environment, as well as community-based research and public engagement in science. Her research focuses on methods for reporting to people on their own exposures to hormone disruptors and other emerging contaminants when health effects are uncertain. Dr. Brody recently led a project connecting breast cancer advocacy and environmental justice in a study of household exposures to endocrine disruptors and air pollutants. Since 1996 Dr. Brody has been the principal investigator of the Cape Cod Breast Cancer and Environmental Study, a case-control study of 2,100 women that includes testing for 89 endrocrine disruptors in homes, along with historical mapping. She led a two-year study of scientific review of evidence on animal mammary gland carcinogens and epidemiologic studies of breast cancer and environmental pollutants, diet, body size, and physical activity.

Presentations


Elements of Successful Product Development Research Applications  

An in-depth review of the elements that go into a successful CPRIT Product Development Research application from members of the Product Development Review Council and the Oversight Committee, along with intellectual property counsel and CPRIT's deputy executive officer and general counsel. This session is relevant to anyone interested in applying for a CPRIT Product Development Research award. 

Moderators

Craig Rosenfeld, MD 
CPRIT

Dr. Rosenfeld is well-known in the field of biotechnology and oncology after a distinguished career as a physician, advocate and entrepreneur. At nearly every turn, he has led essential cancer-fighting initiatives ranging from direct patient care and teaching medical students to directing bone marrow transplant facilities and founding biotechnology startups. He currently serves as CEO at Collaborative Medical Development, a firm pursuing therapies for neurogenerative and psychiatric diseases including Alzheimer's, Parkinson's and ALS. Dr. Rosenfeld is a member of numerous medical organizations including the American Society of Clinical Oncology and the New York Academy of Science. He was also highly involved in the Texas Israel Chamber of Commerce, having previously served on its board of directors.
Speakers

Kristen Doyle 
CPRIT

Ms. Doyle is responsible for overseeing the legal issues that arise as part of CPRIT’s operations, including grant award contract negotiations, intellectual property and revenue sharing agreements, conflicts of interest and confidentiality, and regulatory/compliance issues.  Prior to joining CPRIT, Ms. Doyle was a partner at an Austin-based law firm and served as Vice President of the Board of Directors for the Central Texas Chapter for the Leukemia and Lymphoma Society. 

Ms. Doyle has spent the majority of her legal career practicing administrative law, with an emphasis in the field of energy and regulatory law. She received her undergraduate degree in Public Policy, magna cum laude, from Indiana University and her doctorate of Jurisprudence from the University of Texas at Austin School of Law. In 2012  Ms. Doyle received her Masters of Science in Technology Commercialization from the McCombs School of Business at The University of Texas at Austin.  She has been recognized four times as a Super Lawyers Texas Rising Star by Texas Monthly and named to the 2010 edition of The Best Lawyers in America. 

 

Margaret Sampson, PhD 
Baker Botts LLP

Dr. Sampson has a global, strategic intellectual property transaction and patent counseling practice focused in the areas of life sciences, pharmaceuticals, research tools, and medical devices.  Dr. Sampson has extensive experience advising clients in evaluating patent portfolio positions; analyzing freedom-to-operate issues; identifying and evaluating targets for potential investment, mergers, or acquisitions; and assisting with joint development, inbound, and outbound licensing agreements. Dr. Sampson received a PhD in molecular and human genetics from the Baylor College of Medicine and her doctorate of Jurisprudence from The University of Texas School of Law, where she was editor-in-chief of the Texas Intellectual Property Law Journal.  

Rob Sarisky, PhD 
CPRIT

Dr. Sarisky is an experienced scientific and business professional from the pharmaceutical industry, most recently serving as chief business officer of FORMA Therapeutics, and vice president of Oncology Business Development and Licensing within Janssen Pharmaceuticals, a Johnson & Johnson company. Prior to that role, he held management positions at Centocor and GlaxoSmithKline Pharmaceuticals. Dr. Sarisky received a bachelor of science degree in biology from the University of Scranton, a PhD in genetics from the Pennsylvania State University College of Medicine, completed his postdoctoral training at the Johns Hopkins School of Medicine and holds an MBA in marketing from Lehigh University. He has authored more than 120 publications and patents and served on the editorial boards of two scientific journals and the University of Pennsylvania Executive Advisory Committee for the HHMI Graduate Training in Medical Sciences.

Presentations


1:30 PM
Adapting and Disseminating Evidence Based Prevention Programs 

This session explores recent advancements in disseminating and implementing science relevant to cancer prevention. It focuses on issues of program development and program adaptation, with a discussion on funding opportunities in community settings. 

Speakers

Ross Brownson, PhD 
CPRIT

Dr. Brownson is the Bernard Becker professor at Washington University in St. Louis, with appointments in the Brown School and the Alvin J. Siteman Cancer Center. He is involved in numerous community-level studies designed to understand and reduce modifiable risk factors such as physical inactivity, obesity, and tobacco use. In particular, he is interested in the impacts of environmental and policy interventions on health behaviors and he conducts research on dissemination of evidence-based interventions with a focus on policy settings and health departments. Dr. Brownson is the author of seven books and over 400 peer-reviewed articles. He is active in numerous professional associations such as the American Public Health Association and the Missouri Public Health Association. He is the immediate past-president of the American College of Epidemiology.

Presentations


Moving From Research to Reality 
Two CPRIT grantees offer insights and perspectives on how their projects moved across the continuum from research to product development.   
Speakers

Barry Maurer, MD, PhD 
Texas Tech University Health Sciences Center

Dr. Maurer is a board-certified pediatric oncologist and academic developmental cancer researcher conducting basic laboratory investigations and early phase clinical trials. His major interests are the cellular mechanisms, translational development, and clinical testing of the cytotoxis retinoid, fenretinide, as a dihydroceramide-increasing agent, both as a single agent and in combination with other modulators of ceramide pathways in adult and pediatric tumor systems. He currently holds two investigator-initiated, FDA investigational new drug applications related to this research.

George Georgiou, PhD 
The University of Texas at Austin

Dr. Georgiou holds the Cockrell Chair in Engineering at The University of Texas at Austin, where he serves on the faculties of chemical engineering, molecular biosciences and the Institute for Cell and Molecular Biology. He received his BSc degree from the University of Manchester, U.K. and his master's and PhD from Cornell University. His group is working in molecular biotechnology, antibody engineering and human B cell immunology. Dr. Georgiou was selected in 2013 by Nature Biotechnology as one of the top 20 translational researchers in the world. He has authored more than 220 research publications and is the co-inventor of over 78 issued and pending U.S. patents, of which more than 70 percent have been licensed to 21 biotech and pharma companies. Dr. Georgiou was elected to the National Academy of Engineering (NAE) and to the U.S. Institute of Medicine (IOM) of the National Academy of Sciences. In 2008 he was named as one of the top "100 Chemical Engineers of the Modern Era" by the American Institute of Chemical Engineers. He founded GGMJD LLC (acquired by NASDAQ-traded Maxygen) in 2000, Austin-based Aeglea Biotherapeutics, Inc., and Kyn Therapeutics LLC. 

Presentations


2:30 PM
Research Advances: Updates from CPRIT Grantees 
Come along on a journey from ideas to discoveries. Two CPRIT grantees take you behind the scenes in their labs to talk about their research and the advances they've made in the fight against cancer. 
Speakers

Melanie Cobb, PhD 
The University of Texas Southwestern Medical Center at Dallas

Dr. Melanie Cobb received her undergraduate degree in biochemistry from the University of Chicago and her PhD in biological chemistry from Washington University in St. Louis in the laborabory of Garland Marshall. Following postdoctoral work with Ora Rosen at the Albert Einstein College of Medicine in New York, she joined the Department of Pharmacology at The University of Texas Southwestern Medical Center in Dallas, where she is currently a professor and holds the Jane and Bill Browning, Jr. chair in medical science. Her interests are in cellular regulatory mechanisms.

Philip Lupo, PhD, MPH 
Baylor College of Medicine

Dr. Lupo is a molecular epidemiologiest and assistant professor of pediatrics at Baylor College of Medicine. As a member of the epiCENTER in the Texas Children's Cancer Center, his particular interests are in the genetic and environmental determinants of childhood cancer. He is currently collaborating with other researchers and clinicians, both nationally and internationally, to examine the role of genes and prenatal exposures on the development of childhood cancer, as well as the identification of novel risk factors for late effects among childhood cancer survivors. Dr. Lupo is an active collaborator with the Centers for Disease Control and National Birth Defects Prevention Study (NBDPS). Additionally, he is part of a multi-disciplinary team of experts assessing the intersection of childhood cancer and birth defects. As part of that effort, he is currently the principal investigator of the GOBACK (Genetic Overlap between Anomalies and Cancer in Kids) study. The ultimate goal of Dr. Lupo's research is to discover factors that can be used in childhood cancer prevention efforts and targeted interventions to limit the adverse consequences of childhood cancer treatment.

Presentations


Prevention in Practice: Academic-Community Collaborations 

This interactive session explores the value, challenges and opportunities associated with community organization-academic partnerships on CPRIT Prevention proposals. Panelists include academics and a community organization leader, who will respond to questions about collaboration opportunities across the life span of a CPRIT project, including planning, implementation and evaluation. 

Moderators

Stephen Wyatt, DMD, MPH 
CPRIT Prevention Review Council

Dr. Wyatt is chair of the CPRIT Prevention Review Council and former dean of the College of Public Health at the University of Kentucky. He began serving as dean in November 2004. Prior to that, he focused for six years on research and teaching at UK while serving as the associate director for cancer control at the Markey Cancer Center. During his tenure at UK, Dr. Wyatt was the principal investigator for several large cancer control grants, including the NCI-funded Appalachia Cancer Network and Cancer Information Service and the CDC-funded Prevention Research Center and Comprehensive Cancer Control. Dr. Wyatt is currently the senior associate director for UK's Center for Clinical and Translational Science and the vice president for research for Norton Healthcare in Louisville, Kentucky.
Speakers

Linda Ross, DNP 
Angelo State University

Dr. Ross has more than 30 years of experience in nursing and healthcare/nursing administration. She currently serves as the executive director of the Center for Wellness Engagement and Development and director of The Laura W. Bush Institute for Women's Health at Angelo State University. She co-authored and served as project director for a $1.27 million grant to implement an accelerated/online LVN-RN program. Prior to joining the nursing faculty at Angelo State University in 2005, she served as administrator of a multi-speciality physician clinic. She has worked in various areas of hospital and nursing administration. Dr. Ross is a Certified Professional in Healthcare Quality (CPHQ) and Healthcare Quality Management, and a fellow of the American Institute of Healthcare Quality. She has a DNP from Chatham University, a Master of Science degree from Texas Woman's University and a Bachelor of Science degree in nursing from Baylor University.

Navkiran Shokar, MD, MPH 
Texas Tech University Health Sciences Center, El Paso

Dr. Shokar is associate professor of Family and Community Medicine and Biomedical Sciences, vice chair for research, Department of Family and Community Medicine, and director of Cancer Prevention and Control in the Center of Excellence for Cancer at Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso. Her research interests include interventions in cancer prevention and control, medical decision making, health services research, and cancer health disparities. She is the principal investigator on CPRIT-funded prevention grants for colorectal, breast, and cervical cancer screening programs in El Paso and Hudspeth Counties. They consist of culturally tailored and community based education, clinical service delivery for screening and diagnosis, and navigation.

Shane Chen 
HOPE Clinic

Ms. Chen has extensive years of experience in not for profit and the public sector. She was executive director of the Asian Pacific-Islander American Heritage Association (APAHA) and the community liaison for former Houston City Council Member Gordon Quan.  With strong cultural and health knowledge of the Texas Asian American, Native Hawaiian, and Pacific Islanders’ (AANHPI) communities, Ms. Chen also served on HHS National Partnership for Action, Region Six-Regional Health Equity Council. She is an advocate of health equity for vulnerable individuals and families through community capacity building, raising health literacy and cultural competency, and improving access to care. 

 

Presentations


Resources, Part I - Texas Incubators 

The two Resources panels will explore how incubators, accelerators, and investors enable talented researchers in Texas to take innovation to the next level, furthering a goal of helping entrepreneurs advance science through transformational solutions for cancer patients.

Moderators

Tom Kowalski 
Texas Healthcare & Bioscience Institute

Mr. Kowalski is president and CEO of the Texas Healthcare and Bioscience Institute (THBI) in Austin, Texas.  The Institute is a public policy research organization whose purpose is to promote medical research, development and manufacturing in Texas. THBI consists of leading biotechnology, medical device, agriculture and pharmaceutical companies, universities, private research institutions, chambers of commerce and economic development corporations.  Mr. Kowalski was appointed in 2002 to Governor Rick Perry’s state council on science and biotechnology development. With over thirty years of political and policy experience, Mr. Kowalski was appointed in 1989 by Governor Bill Clements to the board of regents of the Texas State University System. He served as chairman of the board of regents in 1995.  In addition, Mr. Kowalski was chairman of the Texas State University Development Foundation and is the current chairman of the McCoy College of Business Administration advisory council. He is the former chairman of Bio’s Council of State Biotechnology Associations.

Speakers

Emmanuelle Schuler, PhD 
Johnson & Johnson

Dr. Schuler is the site leader for JLABS @TMC, Johnson & Johnson's latest life science incubator. She focuses on bringing together executives, investors, entrepreneurs, thought leaders, clinicians and inventors to create innovative solutions that impact healthcare delivery and patients' lives. She collaborates with J&J Innovation and J&J's corporate venture capital group to attract companies in alignment with their strategic efforts in biopharma, diagnostics, medical devices and consumer healthcare. She brings over 10 years of experience in intellectual capital management, strategic alliances, and joint ventures. Prior to joining J&J, she led IP-based transactions at MD Anderson Cancer Center. Before that, she was responsible for industry-based strategic collaborations at the University of Houston. She consulted with the European Commission on innovation policy issues. She also worked on science policy projects under the mentorship of Nobel Laureate Dr. Richard E. Smalley at Rice University. Dr. Schuler earned a Bachelor of Science degree in chemistry from Université du Québec à Montréal, a PhD in chemistry from McGill University, and a master's in business administration from Rice University.

Terry Zrubek 
Office of the Governor, State of Texas

Mr. Zrubek has valuable and productive experience in both the private and governmental sectors. After receiving a degree in economics from Texas State University, he worked for Newell Manufacturing Company, a Fortune 500 Company that later merged to become Newell Rubbermaid. During his time there, Zrubek focused on numerous aspects of finance, marketing and sales dealing with consumer interests and preferences. Since 2003, he has been employed with the State of Texas, where he has developed an expert level of understanding of state government and its budget, legislative, and policy processes. Zrubek holds an MBA degree from St. Edwards University, with a concentration in corporate finance. During his years as a state governmental employee he served in various capacities for the Texas Department of Public Safety, state Senator Steve Ogden, the Texas Commission on Environmental Quality, the Lower Colorado River Authority, and Governors Rick Perry and Greg Abbott. 

Emma Wollschlager Schwartz, MPH 
Medical Center of the Americas Foundation

Ms. Schwartz is the president of the Medical Center of the Americas (MCA) Foundation. She leads, advocates for, and coordinates the development of the MCA campus. She also manages the foundation's day-to-day operations and coordinates the activities of the foundation's board of directors. Ms. Schwartz is the founder and president of Wollschlager Consulting, LLC, d/b/a W Consulting, LLC, a healthcare management and regulatory compliance consulting company. Prior to launching her own consulting firm, Ms. Schwartz was the director of compliance consulting for Sinaiko Healthcare Consulting, Inc. in Los Angeles, California. Before that, she was the assistant director of legal compliance for Sierra Providence Health Network, a multi-hospital Tenet Healthcare System in El Paso, Texas. At Tenet, she directed both legal and contract compliance efforts. Ms. Schwartz received her bachelor's degree from Stanford University in human biology with a concentration in comparative health policy, and she received her Master of Public Health from the UCLA School of Public Health in health services management.

Presentations


3:15 PM
Poster Group A


Tuesday, November 10

8:00 AM
The Evolution of Precision Oncology - Biological Complexity, Big Data & Big Price 

Despite the enormous promise of precision oncology, technical progress alone is insufficient. Dr. Poste discusses how large scale adoption of molecular profiling in cancer will generate unprecedented amounts of data and the need for new data analytics. 

Speakers

George Poste, PhD 
Arizona State University

Dr. Poste is chief scientist, Complex Adaptive Systems Initiative, Regents’ professor and Del E. Webb Chair in Health Innovation at Arizona State University (ASU). He was the founder and director of the Biodesign Institute at ASU. Dr. Poste serves on the board of directors of Monsanto, Exelixis, Caris Life Sciences, and the scientific advisory board of Synthetic Genomics. Prior to working at ASU, Dr. Poste served as chief science and technology officer and president, R&D, of SmithKline Beecham, where he shepherded the successful registration of 31 drug, vaccine and diagnostic products. He has won numerous awards, published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. A fellow of the Royal Society, Dr. Poste is currently a member of the U.S. Institute of Medicine Board on Global Health and has served on advisory committees for multiple U.S. government agencies in the areas of defense, national security and healthcare.

Presentations


8:45 AM
Accelerating HPV Vaccine Uptake: The President's Cancer Panel Report 

During 2012-2013, the President’s Cancer Panel held workshops to explore underuse of HPV vaccines and ways to accelerate vaccine uptake. In its February 2014 report, the Panel provided specific, targeted, and actionable recommendations to address barriers to uptake of this cancer prevention vaccine. The Panel's report, and actions taken by various stakeholders to implement the report’s recommendations, will be discussed. 

Speakers

Abby Sandler, PhD 
National Cancer Institute

Dr. Sandler has worked at the National Cancer Institute (NCI) since 1999 and has served as executive secretary of the President’s Cancer Panel since January 2005. Since 2013, she also has served as special assistant to the director, NCI Center for Cancer Research, on the Rare Tumors Initiative. Prior to working at NCI, Dr. Sandler was a program director for the Department of Veterans Affairs Medical Research Service in Washington, D.C., and was also a scientist for Pro-Virus, Inc. (now called Wellstat Biologics) in Gaithersburg, Maryland. Her research background focuses on molecular tumor virology and gene therapy. She received her bachelor's in biology from Rensselaer Polytechnic Institute and her PhD in biology from The Johns Hopkins University. Dr. Sandler carried out her postdoctoral research at NCI.

Presentations


9:30 AM
Coffee Break

9:45 AM
Prevention of Hepatocellular Carcinoma (HCC): A Multipronged Approach 
The session includes a discussion of the epidemiology and prevalence of Hepatocellular Carcinoma focusing on Texas and primary risk factors including Hepatitis C virus (HCV) and non-alcoholic fatty liver disease. It also provides an overview of two CPRIT-funded projects approved last May. Drs.Turner and El-Serag review HCV prevention opportunities through baby boomer screening and access to new direct-acting drugs to cure HCV. Attendees will hear about findings from a previously completed program of inpatient baby boomer screening and plans for engaging diverse practices in South-Central Texas and Dallas.
Speakers

Hashem El-Serag, MD, MPH 
Baylor College of Medicine

Dr. El-Serag obtained his medical degree from Al-Arab Medical University in Libya. He completed his internship and residency in internal medicine at Greenwich Hospital, Yale University, and completed a fellowship in clinical gastroenterology at the University of New Mexico, where he also earned a master's degree in public health. In 1999 Dr. El-Serag joined the Michael E. DeBakey VA Medical Center and Baylor College of Medicine in Houston, where he became chief of the Section of Gastroenterology and Hepatology and leader of the Cancer Prevention and Population Sciences at the Dan L. Duncan Cancer Center. His research focuses on the clinical epidemiology and outcomes of several digestive disorders, including hepatocellular carcinoma. His seminal work on hepatocellular carcinoma, "Rising Incidence of Hepatocellular Carcinoma in the United States," was published in the New England Journal of Medicine and has been cited more than 2,000 times. Dr. El-Serag has more than 350 articles published.

Barbara Turner, MD 
The University of Texas Health Science Center at San Antonio

Dr. Turner trained in medicine at the University of Pennsylvania and was a tenured professor of medicine at the University of Pennsylvania School of Medicine when she and her husband were recruited to The University of Texas Health Science Center in San Antonio in 2010.  Dr. Turner now directs the ReACH (Research to Advance Community Health) Center, a collaboration of the Health Science Center and The University of Texas School of Public Health. She has more than 140 peer-reviewed publications and has led several national physician organizations, serving as regent of the American College of Physicians, a national organization or more than 125,000 internists, and as president of the Society of General Internal Medicine (SGIM), a national organization of all the leading researchers and educators in general medicine.

Presentations


University & Biotech Company Alliances  

Texas prides itself on the preeminence of its academic medical centers such as MD Anderson, UT Southwestern, Baylor College of Medicine, UTMB and others.  Forming strategic alliances with these institutions can be a significant achievement for biotech companies that are advancing novel cancer vaccines, therapeutics or diagnostics.  The institutions are becoming very creative in the ways in which they can support the growth and success of these companies and, in some cases, invest in the companies with which they are partnering. The panel of experts will review the types of alliances that have been formed in the past and what we can expect in the future. 

Moderators

Andrew Strong 
Pillsbury Winthrop Shaw Pittman LLP

Mr. Strong is a partner in the Pillsbury law firm's Houston and Austin offices. His practice is focused on the biotech side of life sciences where he assists companies on general corporate, capital market, partnering, IP, employment and regulatory matters.  Mr. Strong is the former president and CEO of Kalon Biotherapeutics, LLC, a biologics and manufacturing company formed by The Texas A&M University System in 2011.  In the span of three years, Kalon grew to a staff of over 100, was a CPRIT awardee and secured over $90 million in contracts from GlaxoSmithKline, MD Anderson, BARDA and others.  In 2014 he oversaw a process that led to the successful sale of Kalon in December to a subsidiary of FUJIFILM Corporation and Mitsubishi Corporation. Prior to joining Kalon, Mr. Strong served as the general counsel and compliance officer for The Texas A&M University System where he was responsible for all legal matters of its 11 universities, seven state agencies and health science center. He received a Bachelor of Science degree from Texas A&M University in civil engineering and is a registered professional engineer in Texas. He also received a Doctorate of Jurisprudence from South Texas College of Law.

Speakers

Ferran Prat, PhD 
The University of Texas MD Anderson Cancer Center

Dr. Prat is vice president of Strategic Industry Ventures, helping the faculty and researchers at The University of Texas MD Anderson Cancer Center develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. Previously, Dr. Prat held a number of industry and academic positions, including vice president, oncology and women's health, at Alere Inc., VP for licensing at Biosite Inc., management consultant at McKinsey & Co., engineer at Chromogenia-Units, and researcher at the University of California at Los Angeles (UCLA). Dr. Prat has a PhD in organic chemistry from UCLA and a law degree from the University of San Diego School of Law.

Patricia Hurn, PhD 
The University of Texas System

Dr. Hurn is vice chancellor for research and innovation at The University of Texas System. She serves as the chief health research officer to the UT System and its six academic health center campuses. She is also an active neuroscientist and is internationally known for her work in understanding the cellular and molecular basis of gender differences in response to experimental brain injury. Dr. Hurn serves as a research professor in neurobiology in The University of Texas at Austin's College of Natural Sciences. She directs a translational laboratory that studies the role of hormone in post-stroke immunology. She holds bachelor’s and master’s degrees of science in nursing, and earned a doctorate in physiology from The Johns Hopkins University, where she went on to become a full professor. At Oregon Health and Science University (OHSU), Dr. Hurn served as professor and vice chair for research in the Department of Anesthesiology and Perioperative Medicine, and as professor of neurology and of physiology and pharmacology.

Clifford Stocks 
Theraclone Sciences, Inc.

Mr. Stocks is CEO of Theraclone Sciences, Inc., a therapeutic antibody company focused on immuno-oncology and the treatment of infectious disease. Previously he helped form and served as chief business officer of Calistoga Pharmaceuticals, Inc. Mr. Stocks brings more than two decades of experience in the biotech industry. His career includes 15 years at ICOS Corporation, where he served as an executive officer and vice president of business development. While at ICOS, he led acquisitions and joint venture activities as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis, and was a key architect of the Lilly ICOS joint venture partnership leading to their $2.3 billion merger in 2007. Previously in his career, Mr. Stocks was a management consultant in the Health Services practice of Booz, Allen & Hamilton, and his early career includes academic research on staff in the department of immunology at the University of Utah and on staff in the department of molecular genetics and cell biology at the University of Chicago, where he also received an MBA degree from the University of Chicago Booth Graduate School of Business.

Steffen Walter 
Immatics US, Inc.

Dr. Walter co-founded Immatics US, Inc. and joined it in 2015 as chief scientific officer. In 2005 Dr Walter joined Immatics Biotechnologies GmbH, the parent company of Immatics US, Inc., as director and head of immunology and later VP of immunology after having successfully completed his PhD on human T-cell biology at the University of Tuebingen (Germany).


10:30 AM
Poster Group B

12:00 PM
Lunch Provided - No Program

1:00 PM
Research Advances: Updates from CPRIT Scholars 
Since its inception, CPRIT funding has helped recruit almost 100 world class cancer researchers to Texas institutions. In this session, two of them will discuss their work to advance our knowledge of cancer. 
Moderators

Patricia Hurn, PhD 
The University of Texas System

Dr. Hurn is vice chancellor for research and innovation at The University of Texas System. She serves as the chief health research officer to the UT System and its six academic health center campuses. She is also an active neuroscientist and is internationally known for her work in understanding the cellular and molecular basis of gender differences in response to experimental brain injury. Dr. Hurn serves as a research professor in neurobiology in The University of Texas at Austin's College of Natural Sciences. She directs a translational laboratory that studies the role of hormone in post-stroke immunology. She holds bachelor’s and master’s degrees of science in nursing, and earned a doctorate in physiology from The Johns Hopkins University, where she went on to become a full professor. At Oregon Health and Science University (OHSU), Dr. Hurn served as professor and vice chair for research in the Department of Anesthesiology and Perioperative Medicine, and as professor of neurology and of physiology and pharmacology.

Speakers

Raghu Kalluri, MD, PhD 
The University of Texas MD Anderson Cancer Center

Dr. Kalluri is chairman and professor of the Department of Cancer Biology and the director of the Metastasis Research Center at The University of Texas MD Anderson Cancer Center, where he also holds the Rebecca and Joseph Brown endowed chair. This year Dr. Kalluri’s lab at MD Anderson received widespread attention for research which could lead to the discovery of a blood test that detects pancreatic cancer early on. Dr. Kalluri received his PhD in biochemistry and molecular biology from the University of Kansas Medical Center and his medical degree from Brown University Medical School. He was a postdoctoral fellow and a research associate at the University of Pennsylvania Medical School and served as professor of medicine at Harvard Medical School (HMS). Dr. Kalluri held appointments in the Department of Biological Chemistry and Molecular Pharmacology at HMS, Harvard MIT division of health sciences and technology, Harvard Stem Cell Institute. He was a research fellow of the HMS Peabody Society. Dr. Kalluri was honored this year with the prestigious Jacob-Henle Medal for his discoveries related to autoimmune and genetic kidney diseases, organ fibrosis and cancer biology. CPRIT funding helped bring Dr. Kalluri to Texas from HMS in 2012.

Yun Huang, PhD 
Texas A&M University Health Science Center

Dr. Huang joined the newly created Center for Epigenetics and Disease Prevention at the Texas A&M Health Science Center Institute of Biosciences & Technology in Houston last year. Her research focuses on epigenetics, or the “software” that runs the human genome, which is one of the most promising targets for disease prevention. Dr. Huang received her doctorate in biochemistry from Georgia State University. In 2009 she joined Dr. Anjana Rao’s laboratory at the Immune Disease Institute at Harvard Medical School as a GSK-Immune Disease Institute Alliance fellow and Leukemia and Lymphoma Society fellow. During her postdoctoral training, Huang significantly contributed to the groundbreaking discovery of TET enzymes, a new type of epigenetic code writer, and was among the first to characterize their biological functions in myeloid cancers and embryonic stem cells. Her discovery resulted in more than 15 peer-reviewed publications in top scientific journals and 1,500 citations in four short years. A CPRIT recruitment grant helped bring her to Texas from the La Jolla Institute for Allergy and Immunology in California. 


Presentations


Resources, Part II - Investors 

The two Resources panels will explore how incubators, accelerators, and investors enable talented researchers in Texas to take innovation to the next level, furthering a goal of helping entrepreneurs advance science through transformational solutions for cancer patients. 

Moderators

Evan Melrose, MD 
Spindletop Capital

Dr. Melrose has 25 years of experience in a variety of health care investments, including research, clinical practice, education, and health policy. Prior to founding Spindletop Capital, he was the founding managing director of PTV Sciences, a Texas-based venture capital firm, and a director with Burrill & Company, a San Francisco-based life science private equity/venture capital firm. He has been a board member and advisor to many organizations including BayBIO-BayBioNest, BioHouston and MD Anderson Technology Review Committee. Dr. Melrose received his bachelor's degree from the University of Pennsylvania, his MD from Indiana University School of Medicine and an MBA from The Wharton School. In 2013 the National Association of Corporate Directors (NACD) elected Dr. Melrose as a NACD Board Leadership Fellow, the highest level of credentialing for corporate directors and corporate governance professionals.

Speakers

Chau Q. Khuong, MPH 
Orbimed Advisors, LLC

Mr. Khuong joined OrbiMed in 2003 as a private equity partner. His experience includes start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He was a summer associate in the new ventures technology transfer group at Columbia University. Mr. Khuong is a Yale Univesity graduate with a bachelor of science degree in molecular, cellular and developmental biology and an MPH with a concentration in infectious disease.

Asish Xavier, PhD 
Johnson & Johnson Innovation - JJDC, Inc.

Dr. Xavier previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, he assisted the company in raising a $30 million second round of financing. Dr. Xavier has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Dr. Xavier received a PhD from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in chemical engineering from the Indian Institute of Technology, Kanpur, India.


Elements of Successful Prevention Applications 
CPRIT Prevention Program Review Council member Dr. Nancy Lee and Chief Prevention Program Officer Rebecca Garcia, PhD, review the elements of a successful CPRIT Prevention program application. This is relevant to anyone interested in applying for a CPRIT Prevention award.
Speakers

Nancy Lee, MD 
CPRIT

Dr. Lee is the deputy assistant secretary of women's health and director of the Office of Women's Health (OWH) at the U.S. Department of Health and Human Services. For most of her career, she was employed at the Centers for Disease Control (CDC), where she focused on cancer screening and epidemiology, safety of contraceptive methods, and HIV infection among women. She has extensive experience in women's health, surveillance systems, and cancer prevention and control. Dr. Lee has published more than 100 articles in scientific journals. From 1999-2004, she served as director of the CDC's division of cancer prevention and control. She joined the OWH in 2011, where her work has concentrated on the Affordable Care Act and women's preventive services, women's health across the life span, and violence against women.

Rebecca Garcia, PhD 

Dr. Garcia heads up CPRIT’s prevention and communications efforts. Ten percent of CPRIT's total funding is dedicated to evidence-based prevention services. Her responsibilities include directing the prevention program and fostering collaboration among the cancer and disease prevention community to maximize CPRIT's impact. In addition, she is responsible for overseeing CPRIT’s strategic communications efforts. Prior to joining CPRIT in 2009, she served as vice president, continuing professional development, for Physicians' Education Resource (PER), a medical education and communications company. Previously, Dr. Garcia was vice president of health sciences for the Susan G. Komen for the Cure where she was responsible for the development and implementation of scientific and outreach strategies. Dr. Garcia managed Komen’s research grants and education programs. Dr. Garcia received a bachelor's degree in medical technology from the University of Texas Health Science Center at Dallas. She obtained a master's degree in instructional design from the Department of Biomedical Communications at the University of Texas Health Science Center at Dallas and a PhD in adult education from the Department of Higher Education at the University of North Texas.

Presentations


2:00 PM
CPRIT Companies in Action: Early Stage Successes 

To date, CPRIT has awarded over $250 million in Product Development Research awards to meritorious projects most likely to bring new drugs, devices and treatments to people. Panelists from three companies discuss their CPRIT-funded projects and early stage successes.  

Moderators

Matt McManus, MD, PhD 
Asuragen

Dr. McManus joined Asuragen in August 2014 with more than 20 years of clinical diagnostic leadership experience, and was previously the CEO and president of PrimeraDx, Inc., a molecular diagnostics company marketing a novel, multiplexed, multi-modal, molecular diagnostics instrument for oncology, infectious disease, and genetic testing. Dr. McManus also served as head of Cleveland Clinic Laboratories and chief operating officer of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He received an MD and PhD from the University of Pennsylvania School of Medicine, MBA from Boston College and his bachelor's from the College of the Holy Cross.
Speakers

David G. Lowe, PhD 
Aeglea BioTherapeutics

Dr. Lowe has been a research scientist leading and managing drug discovery efforts, a venture capitalist investing in emerging and mid-stage life science companies, and most recently a biotechnology entrepreneur. He started his career as a molecular biologist, joining Genentech in 1985 as a postdoctoral fellow and ultimately became a research director. Dr. Lowe was responsible for drug discovery activities in biologics and small molecule therapeutics, efforts that resulted in eight drugs that progressed to clinical development, including two eventual products. In 2002 he joined Skyline Ventures as a Kauffman fellow. As a partner and later managing director, Dr. Lowe led financings in start-ups to mid-stage therapeutics, diagnostics and platform technology companies. In 2013 he became co-founder and CEO of Aeglea BioTherapeutics, an Austin, Texas-based biotechnology company developing engineered human enzymes to treat inborn errors of metabolism and cancer. He also sits on the board of directors and investment committee of MaRS Innovation, a seed stage accelerator.

Paul Lammers, MD 
Mirna Therapeutics, Inc.

Dr. Lammers joined Mirna Therapeutics in November 2009 as its president, CEO, and board director. Previously, he was president of Repros Therapeutics. Dr. Lammers served for six years as the chief medical officer for EMD Serono Inc., a division of Merck KgA, leading a clinical development, medical and regulatory team of 150 people. He began his career with Organon, spending eight years in the commercial and clinical operations in Europe and the U.S. He also served four years as the senior VP of clinical and regulatory affairs at Zonagen in The Woodlands, Texas. Dr. Lammers obtained his medical and master's degrees from Radboud University in Nijmegen, The Netherlands, and moved to the U.S. in 1992.

Ken Moseley, JD 
Bellicum Pharmaceuticals

Ken Moseley joined Bellicum in 2011 as vice president, intellectual property & legal affairs. He has more than 20 years of experience as corporate counsel and VP of intellectual property for companies in the cell and gene therapy space, including Osiris Therapeutics, SyStemix and Applied Immune Sciences. He is a registered U.S. patent attorney and is a member of the State Bars of Texas and California.

 


Research Advances: Updates from CPRIT Grantees 
Three CPRIT grantees discuss their work and what it means in the fight against cancer. 
Speakers

George Georgiou, PhD - Abstract #295
The University of Texas System

Jessica Zavadil - Abstract #296 
The University of Texas Health Science Center at San Antonio

Jessica Zavadil started the MD/PhD Program in 2010 at University of Texas Health Center in San Antonio. She joined Dr. Christi Walter's lab in 2012 when she started graduate school. She has studied new therapeutics for hepatocellular carcinoma for the last three and half years. She also has a special interest in developing better animal models for cancer to improve the translation of therapies from the laboratory bench to the clinic. She was awarded a CPRIT Predoctoral Fellowship in 2014. Jessica plans to complete her PhD this spring and completed medical school in 2018. Upon completion of the MD/PhD program, she will attend an Internal Medicine Residency and Oncology Fellowship.

Vincent Bernard - Abstract #1 
The University of Texas MD Anderson Cancer Center

Vincnet Bernard graduated from Johns Hopkins University with a Bachelor's and Master's in chemical and biomolecular engineering. He then became part of a U54 Partnership for Excellence in Cancer Research MD/PhD program between the University of Puerto Rico and University of Texas Houston MD Anderson Cancer Center. Vincent is currently completing his thesis work in the laboratory of Dr. Anirban Maitra at MD Anderson where he focuses on the potential applications of liquid biopsy in pancreatic cancer.

Presentations


Prevention in Practice: Implementing Programs in Rural Communities 
A discussion of how to innovatively collaborate to achieve effective partnerships that result in advancing delivery of evidence-based preventive services in rural communities. Panelists will explain how unique partners can help bridge the geographic distances, develop new resources, provide flexibility and identify promising new approaches. 
Moderators

Nancy Lee, MD 
CPRIT

Dr. Lee is the deputy assistant secretary of women's health and director of the Office of Women's Health (OWH) at the U.S. Department of Health and Human Services. For most of her career, she was employed at the Centers for Disease Control (CDC), where she focused on cancer screening and epidemiology, safety of contraceptive methods, and HIV infection among women. She has extensive experience in women's health, surveillance systems, and cancer prevention and control. Dr. Lee has published more than 100 articles in scientific journals. From 1999-2004, she served as director of the CDC's division of cancer prevention and control. She joined the OWH in 2011, where her work has concentrated on the Affordable Care Act and women's preventive services, women's health across the life span, and violence against women.

Speakers

Simon Craddock Lee, PhD, MPH 
The University of Texas Southwestern Medical Center

Dr. Lee is an assistant professor of clinical sciences and a member of the Population Sciences and Cancer Control program at The University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center. A medical anthropologist, Dr. Lee was recruited to Dallas from the National Cancer Institute, where he completed postdoctoral training as a cancer prevention fellow. His research examines the culture and organization of cancer prevention and care delivery in safety-net settings, both urban and rural. As a CPRIT grantee, he led the design and implementation of a de-centralized regional delivery model for breast cancer screening and patient navigation across 17 rural and underserved counties serving 18,000 unique women, now supported by a CPRIT competitive renewal grant.

Carol Rice, PhD, RN 
Texas A&M AgriLife Extension Service

Dr. Rice serves as project director for a CPRIT prevention services project, Increasing Breast and Cervical Cancer Screening and Diagnostic Rates in Rural, Frontier, and Border Counties. The project provides education, navigation, transportation and access to clinical services in over 50 counties for uninsured women. She currently is a professor and extension health specialist at Texas A&M AgriLife Extension Service. She specializes in community health and wellness programs delivered through the extension system. Dr. Rice’s past experience includes a variety of clinical positions with a community focus and 21 years teaching undergraduate and graduate nursing at several schools within The University of Texas System. Since coming to the Texas A&M AgriLife Extension Service in 1995, she has worked to support and extend health education conducted by county extension agents. She serves as project director for early detection and cancer awareness for rural Texans and reducing tobacco use by youth in rural communties. Dr. Rice received her bachelor's degree from the University of Wisconsin, a master's from the University of California at San Francisco and a PhD from The University of Texas at Austin. All of her degrees are in nursing.

Rakhshanda Layeequr Rahman, MD 
Texas Tech Health Sciences Center

Dr. Rahman leads a CPRIT-funded prevention project, Access to Breast and Cervical Care for West Texas, which provides screenings and education for residents in 26 Texas Panhandle counties. She joined the Texas Tech University Health Sciences Center (TTUHSC) in 2009 after serving as the founder and director of the interdisciplinary breast fellowship program at the University of Massachusetts. At TTUHSC, Dr. Rahman spearheaded formation of the first nationally accredited Breast Center of Excellence in the Texas Panhandle. Currently, she is the director of the Amarillo Breast Center of Excellence and professor of surgery for the TTUHSC School of Medicine. Dr. Rahman serves on numerous local and national boards and committees including the American Society of Breast Surgeons and the Amarillo Area Breast Health Coalition. She graduated from the Aga Khan University Medical College in Karachi, Pakistan, where she completed her internship and residency. She then spent several years furthering her studies, completing fellowships in breast and general surgery in 2001 at Aga Khan, followed by another fellowship at the University of Arkansas for the medical sciences division of surgical oncology.

Presentations


2:45 PM
CPRIT Companies in Action: Early Stage Successes  
To date, CPRIT has awarded over $250 million in Product Development Research grants. Panelists will discuss the projects their companies are working on and detail early stage successes. 
Moderators

Matt McManus, MD, PhD 
Asuragen

Dr. McManus joined Asuragen in August 2014 with more than 20 years of clinical diagnostic leadership experience, and was previously the CEO and president of PrimeraDx, Inc., a molecular diagnostics company marketing a novel, multiplexed, multi-modal, molecular diagnostics instrument for oncology, infectious disease, and genetic testing. Dr. McManus also served as head of Cleveland Clinic Laboratories and chief operating officer of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He received an MD and PhD from the University of Pennsylvania School of Medicine, MBA from Boston College and his bachelor's from the College of the Holy Cross.
Speakers

David G. Lowe, PhD 
Aeglea BioTherapeutics

Dr. Lowe has been a research scientist leading and managing drug discovery efforts, a venture capitalist investing in emerging and mid-stage life science companies, and most recently a biotechnology entrepreneur. He started his career as a molecular biologist, joining Genentech in 1985 as a postdoctoral fellow and ultimately became a research director. Dr. Lowe was responsible for drug discovery activities in biologics and small molecule therapeutics, efforts that resulted in eight drugs that progressed to clinical development, including two eventual products. In 2002 he joined Skyline Ventures as a Kauffman fellow. As a partner and later managing director, Dr. Lowe led financings in start-ups to mid-stage therapeutics, diagnostics and platform technology companies. In 2013 he became co-founder and CEO of Aeglea BioTherapeutics, an Austin, Texas-based biotechnology company developing engineered human enzymes to treat inborn errors of metabolism and cancer. He also sits on the board of directors and investment committee of MaRS Innovation, a seed stage accelerator.

Paul Lammers, MD 
Mirna Therapeutics, Inc.

Dr. Lammers joined Mirna Therapeutics in November 2009 as its president, CEO, and board director. Previously, he was president of Repros Therapeutics. Dr. Lammers served for six years as the chief medical officer for EMD Serono Inc., a division of Merck KgA, leading a clinical development, medical and regulatory team of 150 people. He began his career with Organon, spending eight years in the commercial and clinical operations in Europe and the U.S. He also served four years as the senior VP of clinical and regulatory affairs at Zonagen in The Woodlands, Texas. Dr. Lammers obtained his medical and master's degrees from Radboud University in Nijmegen, The Netherlands, and moved to the U.S. in 1992.

Ken Moseley, JD 
Bellicum Pharmaceuticals

Ken Moseley joined Bellicum in 2011 as vice president, intellectual property & legal affairs. He has more than 20 years of experience as corporate counsel and VP of intellectual property for companies in the cell and gene therapy space, including Osiris Therapeutics, SyStemix and Applied Immune Sciences. He is a registered U.S. patent attorney and is a member of the State Bars of Texas and California.

 


Prevention Networking Interest Groups 

Prevention grantees will have the opportunity to network, share ideas and best practices, and discuss challenges and solutions to implementing their CPRIT-funded projects.This session is for CPRIT Prevention program grant recipients and potential grant recipients. 


Research Advances: Updates from CPRIT Grantees 
Three CPRIT grantees discuss their work and the advances they've made in their fields.
Speakers

Vijetha Kumar - Abstract #175 
Baylor College of Medicine

Vijetha Kumar currently serves as a research assistant for Baylor College Medicine in Houston. She is intersted in cancer genetics, molecular diagnostis and next generation sequencing technology and informatics.

She earned a Master of Science in biotechnology at the University of Houston-Clear lake; a Master of Science in Life Science at Mount Carmel College and her bachelor's degree at Fergusson College.

Caroline Ahrens, PhD - Abstract #176 
Texas Tech University Institute of Biosciences and Technology

Dr. Caroline Ahrens is currently working with Professors Siva Vanapalli and Wei Li in the Chemical Enginerring Department at Texas Tech University to study circulating tumor cells. Her research focus in CTCs and Exosomes. She earned her doctorate in chemical engineering at MIT in 2015. She has a BSE in chemical engineering from Princeton University.

Peter Davies, MD, PhD - Abstract #297 
Texas A&M University System Health Science Center

Currently Executive Associated Director atTexas A&M University System Health, Dr. Davies is a professor of integrative biology and pharmacolorgy. He previously served as assistant vice present of research at the UT Health Science Center from 2001-2003. Among his current interests is a focus on the biology and pharmacology of the Retinoid X Receptor, which when activated by certain drugs, has show favorable effects in animal models of diabetes and breast cancer and in human leukemia cells. Dr. Davies earned his medical degree and doctorate in biochemistry, both from the University of Miami Medical School.

Presentations


3:45 PM
CPRIT: A Look Forward 
As CPRIT nears the halfway point of its authorization in funding, CEO Wayne Roberts leads a discussion about the challenges and operational planning for the remaining five years and beyond. 
Speakers

Wayne Roberts 
Cancer Prevention and Research Institute of Texas

Mr. Roberts was named CEO of the Cancer Prevention and Research Institute of Texas (CPRIT) in November 2013 after serving since December 2012 as the interim executive director. Prior to four years with The University of Texas Health Science Center at Houston as associate vice president for public policy, his career was weighted towards public finance and budget, especially with respect to higher education.  He held numerous senior positions under Governor Rick Perry in which, among other things, he authored the white paper and draft legislation creating the Texas Emerging Technology Fund to catalyze economic development, including transferring research conducted at universities to the Texas marketplace. He was Lieutenant Governor Bob Bullock’s special assistant for budget and human services following 18 years with the Legislative Budget Board. Mr. Roberts received a bachelor's degree with honors and special honors in government from The University of Texas at Austin and a master's from the Lyndon B. Johnson School of Public Affairs at UT. 

Tom Kowalski 
Texas Healthcare & Bioscience Institute

Mr. Kowalski is president and CEO of the Texas Healthcare and Bioscience Institute (THBI) in Austin, Texas.  The Institute is a public policy research organization whose purpose is to promote medical research, development and manufacturing in Texas. THBI consists of leading biotechnology, medical device, agriculture and pharmaceutical companies, universities, private research institutions, chambers of commerce and economic development corporations.  Mr. Kowalski was appointed in 2002 to Governor Rick Perry’s state council on science and biotechnology development. With over thirty years of political and policy experience, Mr. Kowalski was appointed in 1989 by Governor Bill Clements to the board of regents of the Texas State University System. He served as chairman of the board of regents in 1995.  In addition, Mr. Kowalski was chairman of the Texas State University Development Foundation and is the current chairman of the McCoy College of Business Administration advisory council. He is the former chairman of Bio’s Council of State Biotechnology Associations.

Patricia Hurn, PhD 
The University of Texas System

Dr. Hurn is vice chancellor for research and innovation at The University of Texas System. She serves as the chief health research officer to the UT System and its six academic health center campuses. She is also an active neuroscientist and is internationally known for her work in understanding the cellular and molecular basis of gender differences in response to experimental brain injury. Dr. Hurn serves as a research professor in neurobiology in The University of Texas at Austin's College of Natural Sciences. She directs a translational laboratory that studies the role of hormone in post-stroke immunology. She holds bachelor’s and master’s degrees of science in nursing, and earned a doctorate in physiology from The Johns Hopkins University, where she went on to become a full professor. At Oregon Health and Science University (OHSU), Dr. Hurn served as professor and vice chair for research in the Department of Anesthesiology and Perioperative Medicine, and as professor of neurology and of physiology and pharmacology.

Cam Scott 
American Cancer Society Cancer Action Network

Mr. Scott joined the American Cancer Society in 2005 as director of federal government relations for its high plains division. Previously, he served as legislative director for former Texas Congressman Jim Turner. Mr. Scott earned his undergraduate degree at Southwestern University and a graduate degree from Baylor University.

C. Kent Osborne, MD 
Baylor College of Medicine

Dr. Osborne received his AB and his MD from the University of Missouri. He completed his internship and residency at Johns Hopkins and then spent three years as a clinical associate at the medicine branch of the National Cancer Institute. He was a faculty member at The University of Texas Health Science Center from 1977 to 1999 and served as chief of medical oncology in 1992. Dr. Osborne moved to Baylor College of Medicine in 1999 to direct a new breast center. In 2004 he was named director of the Dan L. Duncan Cancer Center at Baylor.


Questions

Registration

How much does it cost to attend the conference?

Before October 10, 2015 at midnight Central time our attendee rates are:

General Admission: $350.00
Student/Community Advocate: $250.00

After October 10, 2015 at midnight Central time, late registration starts and our rates increase to:

General Admission: $380.00
Student/Community Advocate: $280.00

Under which registration category should I register?

General Admission is our standard attendee type – the majority of registrants will fall into this category.

Choose Student/Community Advocacy if you are currently enrolled in an accredited college, university or professional school/program or if you currently work/volunteer for a community-based organization.

NOTE: When checking in to the conference, Students must show a valid student ID and Community Advocates must provide an affiliate letter on official organization letterhead in order to receive registration discounts.

Speaker should only be used if you have been contacted by the agency’s conference planning team and are an accepted conference speaker.

Are registrants allowed to bring guests?

Each conference attendee is required to register, therefore, guests are not allowed at this time.

Is there a special registration rate for state government employees?

There is no discounted rate for state government employees.

I’m having trouble completing my registration, how can I contact support?

For general registration system support, please contact our helpdesk:

Email: registration@cprit.state.tx.us
Please allow up to 48 business hours for response

Payment

What forms of payment are accepted for registration?

Credit Card (Discover, Visa, Master Card)
Automated Clearing House (ACH)/E-Check
Purchase Order/Physical Check

Checks

Please make checks payable to Cancer Prevention and Research Institute and reference 2015 Conference on the memo line to ensure accurate processing.
(CPRIT Taxpayer Identification Number 26-2482534.)

Purchase Orders

Purchase orders can be submitted for registration payments via fax, email or US mail.

CPRIT’s Mailing Address and Contact Information for Checks and Purchase Orders:

Cancer Prevention and Research Institute of Texas
ATTN: Michelle Huddleston/2015 Conference
PO Box 12097
Austin, Texas 78711

Fax: 512-475-2563
ATTN: Michelle Huddleston/2015 Conference
Email: registration@cprit.state.tx.us

How can I obtain a copy of CPRIT’s W-9 form for my organization’s reimbursement process?

CPRIT’s W-9 can be downloaded here.

Cancellation and Substitutions

What is your cancellation policy?

Cancellation requests will incur a 20% processing fee, per registration, until October 10, 2015 11:59PM CT and after that date/time, payments will no longer be refundable. To request a registration cancellation, please email: registration@cprit.state.tx.us. Responses should be received within two business days.

I have already registered, but I can no longer attend. Can one of my colleagues attend in my place?

Conference attendee substitutions can be made at any time through November 1, 2015, at no additional cost. If you would like to request a substitution, please email: registration@cprit.state.tx.us and provide the name and email address of the person originally registered and contact information (e.g. phone and email) of the person who will be taking their place. Responses should be received within two business days.

Note: Attendees who originally registered under the general admission rate who wish to substitute a student registration instead, will not receive a student discount. Alternatively, attendees originally registered under the student category, who wish to substitute a general admission attendee instead may be subject to an increased registration rate.


Contact

For registration, invoice or general conference related support, please contact us at: